Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cabergoline versus levodopa monotherapy: a decision analysis.

Antje M Smala1, E Annika Spottke, Olaf Machat

  • 1Medical Economics Research Group (MERG), Munich, Germany.

Movement Disorders : Official Journal of the Movement Disorder Society
|July 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the social return on investment of nature-based social prescribing to alleviate loneliness: a randomized controlled trial in Barcelona.

Frontiers in public health·2026
Same author

Cost-effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all-cause mortality among people with opioid use disorder: A retrospective population-based target trial emulation study in British Columbia, Canada, 2010-2020.

Addiction (Abingdon, England)·2026
Same author

DIRECTVALU: ASSESSING INDIRECTNESS OF INDIVIDUAL STUDIES THAT MEASURE PEOPLES' VALUES, UTILITIES, OR THE IMPORTANCE OF OUTCOMES.

International journal of technology assessment in health care·2026
Same author

Integrating Planetary Health in Health Guidelines (GRADE Guidance 46).

Annals of internal medicine·2026
Same author

Protocol for the health economic evaluation of nature-based social prescribing against loneliness alongside the RECETAS trials.

BMC public health·2026
Same journal

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

The LRRK2 G2385R Exonic Variant and Multiple System Atrophy: Findings from the Japan MSA Registry.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alkaline Phosphatases: A Potential Cause of Variability in Therapeutic Response to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion?

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Cabergoline monotherapy shows improved cost-effectiveness for early Parkinson's disease (PD) patients over 60, reducing motor complications. While initial costs are higher, it offers a favorable cost-effectiveness ratio compared to standard therapies.

Area of Science:

  • Health Economics
  • Neurology
  • Clinical Research

Background:

  • Parkinson's disease (PD) management involves balancing treatment efficacy with healthcare costs.
  • Levodopa monotherapy is a common initial treatment, but motor complications can arise.
  • Evaluating new therapeutic options like cabergoline is crucial for optimizing patient outcomes and resource allocation.

Purpose of the Study:

  • To assess the incremental cost-effectiveness of cabergoline versus levodopa monotherapy in early Parkinson's disease (PD) within the German healthcare system.
  • To analyze costs, disease progression, complication incidence, and mortality over a 10-year horizon.
  • To determine the cost-effectiveness of cabergoline, particularly for different age groups.

Main Methods:

  • A cost-effectiveness analysis using a Markov model with a 10-year time horizon.

Related Experiment Videos

  • Input data derived from the "Early Treatment of PD with Cabergoline" clinical trial and German PD network cost data.
  • Inclusion of direct/indirect medical and nonmedical costs, with a 5% annual discount rate and societal perspective.

    • Main Results:

    • Cabergoline monotherapy significantly reduced motor complications compared to levodopa.
    • For patients aged 60 and over, cabergoline was cost-effective per decreased Unified Parkinson's Disease Rating Scale (UPDRS) score (EUR 1,031 per point).
    • Incremental cost per additional motor complication-free patient was EUR 104,400 (<60 years) and EUR 57,900 (≥60 years).

    Conclusions:

    • The decision-analytic model for PD, based on clinical and observed data, suggests cabergoline is a viable option.
    • Despite higher initial costs, cabergoline demonstrates a cost-effectiveness ratio comparable to many established therapies.
    • Cabergoline monotherapy offers a favorable economic and clinical profile for managing early Parkinson's disease, especially in older patients.